BioSpace News Archive

Bausch + Lomb Corporation today announced the election of the 10 directors nominated at its 2023 annual meeting of shareholders (the “Annual Meeting”) held on April 24, 2023.

Anavex Life Sciences Corp. today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference at NASDAQ being held May 2nd, 2023 at 9:30am ET at NASDAQ World Headquarters New York City.

Atsena Therapeutics today announced positive 6-month safety and efficacy data from the ongoing Phase I/II clinical trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1).

Radiant Biotherapeutics emerged from stealth mode unveiling an $8 million seed financing and two significant pharmaceutical partnerships.

TRACON Pharmaceuticals, Inc. today announced that the tribunal in the arbitration against I-Mab conducted under the Rules of Arbitration of the International Chamber of Commerce (ICC) rendered an award to TRACON in the aggregate amount of approximately $23.0 million.

Blue Water Biotech, Inc., a biotechnology company spanning multiple sectors, announced that Blue Water management will attend the American Urological Association Annual Meeting 2023 in Chicago, IL from April 28th to May 1st, 2023, to promote its asset ENTADFI®, an FDA-approved treatment for benign prostatic hyperplasia.

HTG Molecular Diagnostics, Inc., a platform-based life science tools and drug discovery company, provided an update on partnering discussions for its drug discovery business unit.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology (AAN) annual meeting.

Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for hospital and related settings, today announced positive top-line results from its Phase 2 clinical trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.

Proprio, a Seattle-based medical technology company, today announced its surgical navigation platform, Paradigm, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).